Advancements, Challenges, and Future Perspectives in Developing Feline Herpesvirus 1 As a Vaccine Vector

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Sep 27

PMID 39328406

Authors

Xinru Luo

Ruiying Liang

Lin Liang

Aoxing Tang

Shaohua Hou

Jiabo Ding

Zibin Li

Xinming Tang

Affiliations

Soon will be listed here.

Abstract

As the most prevalent companion animal, cats are threatened by numerous infectious diseases and carry zoonotic pathogens such as and , which are the primary causes of human toxoplasmosis and cat-scratch disease. Vaccines play a crucial role in preventing and controlling the spread of diseases in both humans and animals. Currently, there are only three core vaccines available to prevent feline panleukopenia, feline herpesvirus, and feline calicivirus infections, with few vaccines available for other significant feline infectious and zoonotic diseases. Feline herpesvirus, a major component of the core vaccine, offers several advantages and a stable genetic manipulation platform, making it an ideal model for vaccine vector development to prevent and control feline infectious diseases. This paper reviews the technologies involved in the research and development of the feline herpesvirus vaccine vector, including homologous recombination, CRISPR/Cas9, and bacterial artificial chromosomes. It also examines the design and effectiveness of expressing antigens of other pathogens using the feline herpesvirus as a vaccine vector. Additionally, the paper analyzes existing technical bottlenecks and challenges, providing an outlook on its application prospects. The aim of this review is to provide a scientific basis for the research and development of feline herpesvirus as a vaccine vector and to offer new ideas for the prevention and control of significant feline infectious and zoonotic diseases.

References

Guo C, Ma X, Gao F, Guo Y . Off-target effects in CRISPR/Cas9 gene editing. Front Bioeng Biotechnol. 2023; 11:1143157. PMC: 10034092. DOI: 10.3389/fbioe.2023.1143157. View

Willemse M, van Schooneveld S, Chalmers W, Sondermeijer P . Vaccination against feline leukaemia using a new feline herpesvirus type 1 vector. Vaccine. 1996; 14(16):1511-6. DOI: 10.1016/s0264-410x(96)00108-9. View

Yang M, Jiao Y, Yan Y, Li L, Hu X, Jiao Z . Safety and immunogenicity of a TK/ gI/gE gene-deleted feline herpesvirus-1 mutant constructed via CRISPR/Cas9 in feline. Vet Microbiol. 2023; 281:109728. DOI: 10.1016/j.vetmic.2023.109728. View

Smith N, Goulart C, Hayward J, Kupz A, Miller C, van Dooren G . Control of human toxoplasmosis. Int J Parasitol. 2020; 51(2-3):95-121. DOI: 10.1016/j.ijpara.2020.11.001. View

Mishima M, Xuan X, Nishikawa Y, Makala L, Yokoyama N, Nagasawa H . Construction of recombinant feline herpesvirus type 1 expressing Toxoplasma gondii surface antigen 1. Mol Biochem Parasitol. 2001; 117(1):103-6. DOI: 10.1016/s0166-6851(01)00325-5. View

Eschke K, Trimpert J, Osterrieder N, Kunec D . Attenuation of a very virulent Marek's disease herpesvirus (MDV) by codon pair bias deoptimization. PLoS Pathog. 2018; 14(1):e1006857. PMC: 5805365. DOI: 10.1371/journal.ppat.1006857. View

Tartaglia J, Jarrett O, Neil J, Desmettre P, Paoletti E . Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol. 1993; 67(4):2370-5. PMC: 240401. DOI: 10.1128/JVI.67.4.2370-2375.1993. View

Mishima M, Xuan X, Yokoyama N, Igarashi I, Fujisaki K, Nagasawa H . Recombinant feline herpesvirus type 1 expressing Toxoplasma gondi ROP2 antigen inducible protective immunity in cats. Parasitol Res. 2002; 88(2):144-9. DOI: 10.1007/s004360100429. View

Cottingham E, Johnstone T, Hartley C, Devlin J . Use of feline herpesvirus as a vaccine vector offers alternative applications for feline health. Vet Microbiol. 2021; 261:109210. DOI: 10.1016/j.vetmic.2021.109210. View

10.

Shizuya H, Birren B, Kim U, Mancino V, Slepak T, Tachiiri Y . Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector. Proc Natl Acad Sci U S A. 1992; 89(18):8794-7. PMC: 50007. DOI: 10.1073/pnas.89.18.8794. View

11.

Fischer S, Quest C, Dubovi E, Davis R, Tucker S, Friary J . Response of feral cats to vaccination at the time of neutering. J Am Vet Med Assoc. 2007; 230(1):52-8. DOI: 10.2460/javma.230.1.52. View

12.

Becker P, Norder M, Weissmann S, Ljapoci R, Erfle V, Drexler I . Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8⁺ T Cell Epitopes. Vaccines (Basel). 2015; 2(3):581-600. PMC: 4494220. DOI: 10.3390/vaccines2030581. View

13.

Liu B, Robinson M, Han Z, Branston R, English C, Reay P . ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003; 10(4):292-303. DOI: 10.1038/sj.gt.3301885. View

14.

Mengstie M, Teshome Azezew M, Dejenie T, Teshome A, Admasu F, Teklemariam A . Recent Advancements in Reducing the Off-Target Effect of CRISPR-Cas9 Genome Editing. Biologics. 2024; 18:21-28. PMC: 10802171. DOI: 10.2147/BTT.S429411. View

15.

Fargeaud D, Jeannin C, Kato F, Chappuis G . Biochemical study of the Feline Herpesvirus 1. Identification of glycoproteins by affinity. Arch Virol. 1984; 80(2-3):69-82. DOI: 10.1007/BF01310650. View

16.

Wardley R, Berlinski P, Thomsen D, Meyer A, Post L . The use of feline herpesvirus and baculovirus as vaccine vectors for the gag and env genes of feline leukaemia virus. J Gen Virol. 1992; 73 ( Pt 7):1811-8. DOI: 10.1099/0022-1317-73-7-1811. View

17.

Gao J, Li Y, Xie Q, Al-Zaban M, Al-Saeed F, Shati A . Epidemiological Investigation of Feline Upper Respiratory Tract Infection Encourages a Geographically Specific FCV Vaccine. Vet Sci. 2023; 10(1). PMC: 9864582. DOI: 10.3390/vetsci10010046. View

18.

Saxena M, Van T, Baird F, Coloe P, Smooker P . Pre-existing immunity against vaccine vectors--friend or foe?. Microbiology (Reading). 2012; 159(Pt 1):1-11. PMC: 3542731. DOI: 10.1099/mic.0.049601-0. View

19.

Romero N, Tishchenko A, Verhamme R, Wuerzberger-Davis S, Van Waesberghe C, Nauwynck H . Several Alphaherpesviruses Interact Similarly with the NF-κB Pathway and Suppress NF-κB-Dependent Gene Expression. Microbiol Spectr. 2023; 11(4):e0142123. PMC: 10434116. DOI: 10.1128/spectrum.01421-23. View

20.

Chen T, Zhou X, Qi Y, Mi L, Sun X, Zhang S . Feline herpesvirus vectored-rabies vaccine in cats: A dual protection. Vaccine. 2019; 37(16):2224-2231. DOI: 10.1016/j.vaccine.2019.03.008. View